India: Eculizumab Approved by CDSCO for aHUS & PNH
After years of waiting, eculizumab Soliris(R) has been approved by India’s Central Drugs Standard Control Organisation (CDSCO) as an approved drug…
FDA has a record about aHUS
In 2023 a group from the aHUS community met with the FDA to talk to them about living with aHUS and…
Discontinuation – no longer needing complement inhibition
Complement inhibition treatment discontinuation is a topic that Global Action has led on in the aHUS patient advocacy world for several…
Treatment Discontinuation- do doctors and patients think alike?
Recently a novel article about complement inhibitor treatment discontinuation was published. Novel because of the research method used to produce its…
Eculizumab biosimilars available in Europe and USA
There are now licensed biosimilars to eculizumab available in Europe and also in the USA ( see previous article and further…
Choice of aHUS treatments
In making a choice aHUS patients’ preferences among treatments like eculizumab (and its biosimulars) , ravulizumab, crovalimab, and iptacopan it largely…
Discontinuing complement inhibitor treatment
It is now just over 3 months since a discontinuing treatment decision making model was proposed to help aHUS patients make…
aHUS awareness day and aHUS alliance Global Action
Introduction Atypical Hemolytic Uremic Syndrome (aHUS) is a rare, life-threatening disease that remains largely unfamiliar to the general public and even…
AN aHUS PATIENT’S TREATMENT DISCONTINUATION MODEL
Without any further comment here is the model mentioned in the previous article ( which if you have not already seen…